Highest-materiality recent filing
WTW shareholders approve all proposals at 2026 AGM; directors elected, say-on-pay passed
All nine director nominees elected; Paul Reilly received most against votes (2.6M against of 84.4M cast).
WTW Q1 2026: revenue $2.4B (+8% YoY), adj. diluted EPS $3.72 (+19%), organic growth 3%
Revenue $2.412B (+8% YoY); organic growth 3%; diluted EPS $3.10 (+33%).
WTW Q4 adj. EPS $8.12 (+2%), organic rev +6%; FY adj. EPS $17.08 (+5%)
Q4 revenue $2.94B (organic +6%); adj. EPS $8.12 (+2%); operating margin 34.6%.
WTW completes acquisition of Newfront; expands U.S. middle market & tech capabilities
Completed acquisition of Newfront, a top-40 U.S. broker specializing in tech, fintech, and life sciences.
WTW enters $775M delayed draw term loan to finance Newfront acquisition
Delayed draw term loan facility of $775M, unsecured, matures 3 years from initial draw or 3 years after 2 months post-acquisition.
Willis Towers Watson issues $1B in senior notes to fund Newfront acquisition & refinance debt
Issued $700M 4.550% notes due 2031 and $300M 5.150% notes due 2036; net proceeds ~$990M.
Willis North America prices $1B senior notes; proceeds tied to Newfront deal
Priced $700M 4.550% notes due 2031 and $300M 5.150% notes due 2036.
WTW to acquire Newfront for $1.3B to expand U.S. middle-market and tech capabilities
Upfront payment of $1.05B ($900M cash + $150M equity) plus up to $250M contingent consideration; total $1.3B.
WTW reports Q3 2025 adjusted EPS $3.07 (+11% YoY); organic revenue growth 5%
Revenue $2.29B flat YoY (organic +5%); diluted EPS $3.11 vs loss $16.44 prior year.
WTW Q3 adj EPS $3.07 (+11% YoY); organic revenue +5%; margins expand 230 bps
Revenue $2.29B flat YoY as TRANZACT sale offset; organic revenue grew 5%.
WTW enters $1.5B revolving credit facility, maturing 2030
$1.5B revolving credit facility maturing October 17, 2030, replacing prior 2021 credit agreement.
WTW Q2 2025: Adj. EPS $2.86 (+20% YoY), organic revenue +5%, margins expand
Revenue $2.26B flat (organic +5%); Diluted EPS $3.32 (+144%), Adjusted EPS $2.86 (+20%).
Paul Reilly succeeds Paul Thomas as non-executive Chair of Willis Towers Watson
Shareholders elected all 9 director nominees; votes ranged from 85.2M to 87.9M in favor.
WTW Q1 revenue -5% to $2.2B; organic +5%; adj. EPS flat at $3.13
GAAP diluted EPS $2.33 (+27% YoY); adjusted diluted EPS $3.13 (flat YoY).
WTW appoints Paul Reilly as Non-Executive Chair; Paul Thomas to retire at 2025 AGM
Paul Thomas retires as Non-Executive Chair at the 2025 AGM (May 2025) and will not stand for re-election.
WTW Q4 adjusted EPS $8.13 (+9%); FY adjusted EPS $16.93 (+17%); revenue up 5% organic
Q4 revenue $3.04B (+4% reported, +5% organic); FY revenue $9.93B (+5% reported and organic).
WTW completes sale of TRANZACT to GTCR and Recognize
Sale closed on Dec 31, 2024; announced Jan 2, 2025.
WTW Q3 adj. EPS $2.93 beats; revenue up 6% organic; FY24 guidance reaffirmed
Revenue $2.29B, up 6% YoY (organic 6%); segments: HWC +4%, R&B +10%.
WTW to sell TRANZACT for $632.4M; expects Q3 impairment charges of $1.6–$2.1B
Sale to GTCR and Recognize at $632.4M subject to adjustments; expected close by end of 2024.
WTW Q2 revenue $2.27B (+5%), adj. EPS $2.55 (+24%); raises 2024 outlook low end
Revenue $2.27B, reported +5%, organic +6%; diluted EPS $1.36 (+55%), adjusted diluted EPS $2.55 (+24%).
All 10 director nominees elected; highest against votes: Carl Hess (3.9M) and Paul Thomas (4.1M).
WTW Q1 revenue up 4% to $2.34B; adj. EPS $3.29 beats prior year; guidance reaffirmed
Q1 revenue $2.34B (+4% reported, +5% organic); diluted EPS $1.83 (down 3%); adjusted diluted EPS $3.29 (+16% YoY).
Willis Towers Watson issues $750M 5.900% Senior Notes due 2054; proceeds to repay 2024 notes
Willis North America Inc. issued $750M aggregate principal of 5.900% Senior Notes due March 5, 2054.
WTW subsidiary prices $750M of 5.900% senior notes due 2054; proceeds to repay 2024 notes
Willis North America Inc. priced $750M aggregate principal of 5.900% senior unsecured notes due 2054; net proceeds ~$739M.
WTW Q4 revenue up 7% to $2.9B; adjusted EPS $7.44 (+18% YoY); FY2024 guidance reaffirmed
Q4 revenue $2.91B (+7% reported, +6% organic); FY revenue $9.48B (+7% reported, +8% organic).
WTW Q3 revenue up 11% to $2.2B; adjusted EPS up 2% to $2.24; GAAP EPS down 25%
Revenue $2,166M, +11% reported, +9% organic; HWC +9% organic, R&B +10% organic.
WTW Q2 revenue up 6% but adjusted EPS down 12%; lowers 2024 margin and EPS targets
Revenue $2.16B (+6% YoY, organic +7%); adjusted Diluted EPS $2.05 (down 12%).
Willis Towers Watson announces Adam Garrard to become chairman of Risk and Broking in Q3 2024
Adam Garrard will assume the role of chairman, Risk and Broking in Q3 2024.
Willis Towers Watson shareholders approve all proposals at 2023 AGM
All 10 director nominees elected with FOR votes ranging from 92.7M to 93.2M; broker non-votes 3.2M shares.
Willis North America Inc. issues $750M 5.350% Senior Notes due 2033
Issued $750M aggregate principal of 5.350% Senior Notes due May 15, 2033.
WTW subsidiary prices $750M 5.35% senior notes due 2033
Willis North America priced $750M in 5.350% senior notes maturing 2033.
WTW Q1 revenue $2.24B, +8% organic; diluted EPS $1.88, +83% YoY
Revenue $2.24B (+4% reported, +8% organic); diluted EPS $1.88 (+83% from $1.03).
WTW Q4 adjusted EPS $6.33, +12% YoY; organic revenue growth 5%; full year adjusted EPS +16%
Q4 2022 revenue $2.72B (+1% reported, +5% organic); full year revenue $8.87B (-1% reported, +4% organic).
WTW adjusts 2022 incentive targets post-Russian divestiture
Committee modified three-year performance targets for 2022 PSU awards to align with recast 2024 financial targets post-Russian divestiture.
WTW appoints three new directors; two incumbents won't stand for re-election
Stephen Chipman (ex-Grant Thornton CEO), Jackie Hunt (ex-Allianz AM chair), and Fredric Tomczyk (ex-TD Ameritrade CEO) join Board effective April 1, 2023.
WTW Q3: adj EPS $2.20 (+27%), organic rev +6%, raises cost-savings target
Total rev $1.95B (-1% reported, +6% organic); adj op margin 14.5% (+110 bps).
WTW Q2 GAAP EPS $0.97, adjusted EPS $2.32; raises transformation savings target to $80M+
Total revenue $2.031B, down 3% YoY; organic growth +3%.
WTW shareholders approve all proposals at 2022 AGM, including 2M share increase under equity plan
All eight director nominees elected; Paul Reilly appointment effective Oct 1, 2022.
Willis Towers Watson subsidiary issues $750M 4.650% Senior Notes due 2027
Issued $750M aggregate principal of 4.650% Senior Notes due June 15, 2027.
Willis Towers Watson subsidiary prices $750M 4.65% Senior Notes due 2027
Principal amount $750M, interest rate 4.650%, maturity 2027; closing expected May 19, 2022.
WTW Q1 revenue -3% to $2.16B, net income drops 83% to $125M, adj EPS +22% to $2.66
Total revenue $2.16B, down 3% YoY; organic growth 2%.
WTW realigns to two segments, provides recast 2019-2021 revenue and margin data
Effective Jan 1, 2022, WTW consolidated four segments into Health, Wealth & Career (HWC) and Risk & Broking (R&B).
Willis Towers Watson revamps 2022 incentive plans and CEO Carl Hess's severance
2022 STI program: 66.7% enterprise financial (adjusted net revenue & adjusted operating income), 33.3% individual; payout 50%-200% of target.
WTW Q4 2021 revenue $2.71B (+1%); adj. EPS $5.67 (+9%); full-year free cash flow $1.91B (+23%)
Q4 revenue $2.71B, +1% YoY; organic revenue growth 4% for Q4 and 6% for full year 2021.
Willis Towers Watson to change Nasdaq ticker symbol to 'WTW' on Jan 10, 2022
Ticker symbol changes from 'WLTW' to 'WTW' effective at market open on January 10, 2022.
Willis Towers Watson announces four directors not standing for re-election; new chair appointed
Anna Catalano, Wendy Lane, Wilhelm Zeller will not stand for re-election at 2022 AGM; Victor Ganzi previously announced departure.
Carl Hess named CEO of Willis Towers Watson effective Jan 1, 2022; compensation set at $7.25M LTI
Carl Hess appointed CEO effective Jan 1, 2022; receives $7.25M 2022 LTI award, $1M base salary, 175% STI target.
WTW and AJG amend Willis Re sale agreement; set closing dates and fix exchange rates
Closing Letter Agreement signed December 1, 2021 amends SAPA for Willis Re sale.
Willis Towers Watson sells Willis Re to Gallagher for $3.25B cash plus up to $750M earnout
Sale closed Dec 1, 2021; total upfront cash $3.25B, earnout up to $750M payable in 2025.
Willis Towers Watson appoints four new directors, targets $300M+ cost savings by 2024
New directors: Inga Beale, Fumbi Chima, Michael Hammond, Michelle Swanback; three on Jan 1, Chima on April 1.
The Board has selected Paul Reilly, an independent director of the Board, to become the Non-Executive Chair of the Board effective as of the conclusion of the 2025 AGM, subject to his re-election.
Paul Thomas, the current Non-Executive Chair of the Board of Directors (the “Board”) of Willis Towers Watson Public Limited Company (the “Company”), informed the Board that he intends to retire at the end of his current term and will not stand for reelection at the Company’s 2025 Annual Meeting of Stockholders (“AGM”).
upon the arrival of Lucy Clarke as president, Risk & Broking
Adam Garrard will assume the role of chairman, Risk and Broking
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
two current directors, Mr. Brendan O'Neill and Ms. Linda Rabbitt, gave notice to the Company that they will not be standing for re-election at the Company's next Annual General Meeting, to be held in the second quarter of 2023.
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
On December 7, 2022, the Board of Directors (the "Board") of Willis Towers Watson (the "Company") appointed Mr. Stephen Chipman, Ms. Jackie Hunt, and Mr. Fredric Tomczyk to the Board, each with a start date effective April 1, 2023.
two current directors, Mr. Brendan O'Neill and Ms. Linda Rabbitt, gave notice to the Company that they will not be standing for re-election at the Company's next Annual General Meeting, to be held in the second quarter of 2023.
On December 28, 2021, each of Anna Catalano, Wendy Lane and Wilhelm Zeller provided notice to Willis Towers Watson Public Limited Company (the “Company”) that they had definitively concluded that they will not be standing for re-election to the Board of Directors (the “Board”) at the 2022 Annual General Meeting of Shareholders (“AGM”).
The Board has also appointed Paul Thomas to serve as the next Non-Executive Chair of the Board, succeeding Victor Ganzi at the conclusion of his term at the 2022 AGM.
On December 28, 2021, each of Anna Catalano, Wendy Lane and Wilhelm Zeller provided notice to Willis Towers Watson Public Limited Company (the “Company”) that they had definitively concluded that they will not be standing for re-election to the Board of Directors (the “Board”) at the 2022 Annual General Meeting of Shareholders (“AGM”).
Max materiality 0.85 · Median 0.62 · Most common event earnings